Edwards Lifesciences Corporation (EW)
Edwards Lifesciences is a medical technology company that specialises in replacing damaged heart valves without the need for open-heart surgery.
Is Edwards Lifesciences Corporation a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: High profit margins on specialised medical products. Worth weighing: No dividend payments for income-focused investors.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Edwards Lifesciences Corporation do?
The company focuses on patients with structural heart disease, creating advanced artificial valves and monitoring tools used in intensive care. Sales of these high-tech medical devices to hospitals and surgeons worldwide are what pay the bills. Their edge rests on how they continue to innovate in the heart-valve market to stay ahead of competitors while managing the high costs of medical research.
On our factor screen it looks strongest on momentum and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 14% over the year
- ✓Very profitable - turns about 15% of sales into profit
- !High P/E of 56 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- Momentum screens high
- Value screens low
- Income screens low
Does Edwards Lifesciences Corporation pay a dividend?
No - Edwards Lifesciences Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Edwards Lifesciences Corporation have more cash or more debt?
It holds about $4.25B in cash against about $704.40M of debt - so it has net cash of about $3.55B. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Edwards Lifesciences Corporation's numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Edwards Lifesciences Corporation actually fallen?
Over the last 2 years of daily prices, Edwards Lifesciences Corporation fell as much as −13% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Edwards Lifesciences Corporation?
About 93% of Edwards Lifesciences Corporation, or about 93 in every 100 shares, is held by big institutions such as pension and index funds. The rest, roughly 6%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Edwards Lifesciences Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of Edwards Lifesciences Corporation's sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £22 covers making the product or service, £63 goes on running costs, tax and interest, and about £15 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does Edwards Lifesciences Corporation report earnings, and how did recent quarters go?
Edwards Lifesciences Corporation is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-23 | $0.74 | $0.78 | Beat +5% |
| 2026-04-23 | $0.73 | $0.78 | Beat +7% |
| 2026-02-10 | $0.62 | $0.58 | Missed -6% |
| 2025-10-30 | $0.59 | $0.67 | Beat +13% |
| 2025-07-24 | $0.62 | $0.67 | Beat +8% |
| 2025-04-23 | $0.60 | $0.64 | Beat +7% |
Across the last 6 quarters here, Edwards Lifesciences Corporation came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Edwards Lifesciences Corporation?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Dominance in the ageing population heart-care market
Significant changes to healthcare reimbursement policies
What are the pros and cons of Edwards Lifesciences Corporation?
A balance check, not a score or verdict.
- High profit margins on specialised medical products
- Strong double-digit revenue growth: How fast the company's sales grew versus a year ago.
- Leading position in a niche, essential healthcare market
- No dividend payments for income-focused investors
- High valuation multiples compared to broader market averages
- Heavy reliance on a specific segment of heart surgery
- Strict and unpredictable medical regulatory hurdles
- Potential for new medical technologies to disrupt current products
- Dependence on hospital budgets and government healthcare funding
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in revenue growth below industry averages
- Major safety recalls or clinical trial failures for key products
Common questions about Edwards Lifesciences Corporation
Does Edwards Lifesciences Corporation pay a dividend?
No - Edwards Lifesciences Corporation does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Edwards Lifesciences Corporation report earnings next?
Edwards Lifesciences Corporation is next scheduled to report results on about 2026-10-29. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Boston Scientific Corporation
Veeva Systems Inc.
Danaher Corporation
GE HealthCare Technologies Inc.
Insulet Corporation
Stryker Corporation
Mettler-Toledo International Inc.
Abbott LaboratoriesBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.